Trials / Completed
CompletedNCT06558513
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Initial Efficacy of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Evopoint Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XNW5004 tablets | XNW5004 an EZH2 inhibitor, BID, administered in continuous |
Timeline
- Start date
- 2021-08-03
- Primary completion
- 2025-08-30
- Completion
- 2025-08-30
- First posted
- 2024-08-16
- Last updated
- 2026-01-12
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06558513. Inclusion in this directory is not an endorsement.